Current Report Filing (8-k)
October 14 2016 - 6:18AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): October 10, 2016
ADVERUM BIOTECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-36579
|
|
20-5258327
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File No.)
|
|
(I.R.S. Employer
Identification No.)
|
1035 OBrien Drive
Menlo Park, CA 94025
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (650) 272-6269
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a12)
|
☐
|
Pre-commencement communication pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e4(c))
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(b), (c)
The Board of
Directors (the
Board
) of Adverum Biotechnologies, Inc. (the
Company
) announced today that on October 10, 2016, Amber Salzman, Ph.D. was appointed Chief Executive Officer of the Company, effective October 14,
2016. The Board also announced that, effective October 14, 2016, Paul B. Cleveland, the Companys former Chief Executive Officer, will serve as Executive Chairman of the Board.
Dr. Salzman, age 54, has served as a director and as the President and Chief Operating Officer of the Company since the Companys
combination with Annapurna Therapeutics SAS (
Annapurna
) in May 2016. Prior to the combination, Dr. Salzman served as President and Chief Executive Officer of Annapurna from January 2014 through May 2016. Prior to founding
Annapurna, Dr. Salzman served as Chief Executive Officer of Alophera Therapeutics, Inc., a rare disease company, from January 2012 to December 2013 and as a director and the President and Chief Executive Officer of Cardiokine, Inc., a specialty
pharmaceutical company, from May 2009 until its acquisition by Cornerstone Therapeutics, Inc. in December 2011. Prior to that, as a member of GlaxoSmithKline plcs R&D executive team, Dr. Salzman led an organization of around 2,000
employees and consultants that planned and managed GlaxoSmithKlines drug-development projects and was accountable for clinical trials that were comprised of more than 30,000 patients worldwide. Dr. Salzman is also the President of the
Stop ALD Foundation, a patient-advocacy group focused on driving improvements in treatments for patients with adrenoleukodystrophy and has led initiatives to accelerate drug development and moderate costs, as well as establish a Development Support
Center, in India. She is on the board of directors of the Drexel University Dornsife School of Public Health and ALD Connect, Inc., which is a consortium of academic, industry and patient advocates. Dr. Salzman received a B.A. from Temple
University and a Ph.D. from Bryn Mawr College.
In connection with the Companys combination with Annapurna, Dr. Salzman
received 629,766 shares of the Companys common stock in exchange for her Annapurna capital stock. There are no other transactions between Dr. Salzman and the Company requiring disclosure under Item 404(a) of Regulation S-K.
Item 7.01
|
Regulation FD Disclosure.
|
On October 14, 2016, the Company issued a press release (the
Appointment Press Release
) announcing the Companys leadership changes. A copy of the Appointment Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item
7.01.
The information set forth in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act
), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any
other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
On October 14, 2016, the Company issued a press release titled
Adverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program (the
A1AT Press Release
). A copy of the A1AT Press Release is filed herewith as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Appointment Press Release, dated October 14, 2016.
|
|
|
99.2
|
|
A1AT Press Release, dated October 14, 2016.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: October 14, 2016
|
|
|
|
ADVERUM BIOTECHNOLOGIES, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Leone Patterson
|
|
|
|
|
|
|
Leone Patterson, Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Appointment Press Release, dated October 14, 2016.
|
|
|
99.2
|
|
A1AT Press Release, dated October 14, 2016.
|
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2024 to May 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From May 2023 to May 2024